Researchers at the University of Liège have now confronted this question head-on in a review published in Trends in Molecular Medicine, arguing that the field’s long search for a single decisive biomarker may have been looking for the wrong kind of answer. Michael Herfs, an oncologist at the GIGA Institute in Liège, along with colleagues Diane Bruyère and Romane Geuzaine, contends that no viral, immune or molecular marker identified to date can reliably separate self-resolving infections from those destined to progress. Their analysis suggests the problem is not a shortage of candidate markers but a fundamental misunderstanding of what kind of biological system HPV-driven carcinogenesis actually is.

The core of the difficulty is that HPV-associated cancer development is not a linear process with a single molecular switch. It is a dynamic, multi-layered phenomenon in which the outcome depends on the interplay of viral characteristics, the host’s immune response, genetic and epigenetic alterations, the local microbiota, hormonal influences and broader environmental factors. On top of these interacting variables sit stochastic events, most notably the accumulation of mutations driven by virus-induced genomic instability. Two patients infected with the same viral type can follow radically different trajectories because the determinants of progression are distributed across biological scales rather than concentrated in one measurable signal.

This complexity helps explain why decades of biomarker research have produced incremental improvements rather than a decisive breakthrough. Viral load measurements, E6 and E7 oncogene expression, methylation patterns, immune cell profiling and a host of other candidate indicators have each shown promise in isolated studies, yet none has achieved the predictive accuracy needed to transform clinical decision-making. Herfs crystallizes the field’s predicament in a striking observation: perhaps the main challenge is no longer to discover a new biomarker, but to understand how all the biological mechanisms interact to determine the outcome of an HPV infection. The framing represents a conceptual shift from reductionist marker-hunting toward systems-level interpretation.

It is precisely this shift that recent technological developments have made feasible. High-throughput molecular analysis platforms can now generate vast datasets capturing gene expression, epigenetic modification, viral integration sites and immune signatures simultaneously, while artificial intelligence and machine learning approaches offer the computational tools to integrate these heterogeneous data streams into coherent predictive models. Rather than asking whether a single marker predicts progression, integrative models can weigh dozens or hundreds of features at once, potentially capturing the multi-factorial nature of carcinogenesis that has defeated simpler approaches.

The Liège team sees particular promise in using these models to distinguish between the possible trajectories of an infection or a low-grade precancerous lesion: spontaneous regression, persistence without progression, advancement to a more serious lesion, or evolution toward invasive cancer. Bruyère, a researcher at the Laboratory of Experimental Pathology, explains that artificial intelligence and integrative models could help clarify the diversity of biological trajectories observed in patients and ultimately enable a more personalised form of risk assessment. In practical terms, this would mean moving beyond the binary categorizations of current screening toward a graduated risk profile that reflects the actual biology of each individual infection.

The clinical stakes of such a capability are considerable. Current management of HPV-positive screening results and low-grade lesions relies on HPV testing, cytology and histopathological analysis, supplemented by monitoring protocols that are only weakly personalised. This one-size-fits-all approach generates a well-documented burden of unnecessary colposcopies, repeat biopsies and anxiety-inducing follow-up for patients whose infections would have resolved regardless, while simultaneously risking under-surveillance in the minority whose lesions are genuinely dangerous. A validated predictive framework could tailor follow-up intensity to actual risk, reducing overtreatment and its associated costs and harms while concentrating clinical attention where it is most needed.

However, the researchers are careful to temper expectations with an acknowledgment of the current gap between promise and practice. These new models have not yet been sufficiently validated for routine clinical use, and the path from an encouraging computational result to a deployable diagnostic involves rigorous external validation, standardization of input data, regulatory approval and demonstration of clinical utility across diverse populations. The history of biomarker research in oncology offers cautionary examples of tools that performed impressively in retrospective datasets but faltered in prospective clinical testing. The Liège authors position integrative AI approaches as the most promising avenue for improving risk stratification, not as a finished solution.

Their broader conclusion reframes the research agenda for the field. Rather than continuing to pursue the elusive single indicator that will cleanly predict progression, the future lies in a better overall understanding of the biology of HPV infections as integrated biological systems. This perspective aligns with wider trends in cancer research, where multi-omics profiling and machine learning are increasingly applied to problems whose complexity resists traditional reductionist methods. For HPV specifically, the approach could eventually unify viral genomics, host immunology, epigenetics and microbiome data into models that reflect the true determinants of infection outcome.

If that vision matures, the practical consequences could extend well beyond cervical cancer prevention. Persistent oncogenic HPV infection is also implicated in a rising proportion of oropharyngeal cancers and in anogenital malignancies, and improved risk prediction would benefit screening and surveillance strategies across all of these sites. For now, patients and clinicians must continue working with the imperfect tools of cytology, HPV genotyping and histopathology, but the Liège analysis offers a clear-eyed map of where the field must go next: away from the search for a molecular oracle and toward a genuinely integrative understanding of how viral and host biology combine to decide, infection by infection, whether the outcome is clearance or cancer.

Subject of Research: Prediction of progression risk in oncogenic human papillomavirus infection using integrative biomarkers and artificial intelligence

Article Title: Human papillomavirus: Can we finally predict which infections will progress to cancer?

Article References: Human papillomavirus: Can we finally predict which infections will progress to cancer?. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: HPV, human papillomavirus, cancer risk prediction, biomarkers, artificial intelligence, cervical cancer, carcinogenesis, risk stratification, molecular medicine, precancerous lesions, University of Liège, personalised medicine